These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27130831)

  • 1. Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.
    Levin PA; Brekken RA; Byers LA; Heymach JV; Gerber DE
    J Thorac Oncol; 2016 Aug; 11(8):1357-1362. PubMed ID: 27130831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXL and acquired resistance to EGFR inhibitors.
    Postel-Vinay S; Ashworth A
    Nat Genet; 2012 Jul; 44(8):835-6. PubMed ID: 22836088
    [No Abstract]   [Full Text] [Related]  

  • 3. AXL kinase as a novel target for cancer therapy.
    Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
    Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
    Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
    Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
    Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput high-content imaging assays for identification and characterization of selective AXL pathway inhibitors.
    Tang H; Yang J; Shen DR; Calambur D; Witmer M; Wu S; Carpenter B; Zhang Y; Gao M; Constantine K; Zhang L; Cvijic ME
    Assay Drug Dev Technol; 2014; 12(1):80-6. PubMed ID: 24547742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis.
    Hoj JP; Mayro B; Pendergast AM
    Cell Rep; 2019 Dec; 29(11):3421-3434.e8. PubMed ID: 31825826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma.
    Iida S; Miki Y; Suzuki T; Mori K; Saito M; Niikawa H; Kondo T; Yamada-Okabe H; Sasano H
    Anticancer Res; 2014 Apr; 34(4):1821-7. PubMed ID: 24692715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
    Ramkumar K; Stewart CA; Cargill KR; Della Corte CM; Wang Q; Shen L; Diao L; Cardnell RJ; Peng DH; Rodriguez BL; Fan YH; Heymach JV; Wang J; Gay CM; Gibbons DL; Byers LA
    Mol Cancer Res; 2021 Mar; 19(3):485-497. PubMed ID: 33172976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (-)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells.
    Namiki K; Wongsirisin P; Yokoyama S; Sato M; Rawangkan A; Sakai R; Iida K; Suganuma M
    Sci Rep; 2020 Feb; 10(1):2444. PubMed ID: 32051483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic aspects of the Axl/Gas6 molecular system.
    Di Stasi R; De Rosa L; D'Andrea LD
    Drug Discov Today; 2020 Dec; 25(12):2130-2148. PubMed ID: 33002607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 17. Receptor tyrosine kinases in osteosarcoma: not just the usual suspects.
    Rettew AN; Getty PJ; Greenfield EM
    Adv Exp Med Biol; 2014; 804():47-66. PubMed ID: 24924168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors.
    Feneyrolles C; Guiet L; Singer M; Van Hijfte N; Daydé-Cazals B; Fauvel B; Chevé G; Yasri A
    Bioorg Med Chem Lett; 2017 Feb; 27(4):862-866. PubMed ID: 28094183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.
    Kim NY; Suh YA; Kim S; Lee C
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32219334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
    Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
    Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.